Novartis' Entresto, the clear-cut market leader in heart failure, has been soul-searching since its highly touted trial in an untreated population fell flat. Now, a surprise competitor has cropped up—but Merck and Bayer's upstart could actually give Novartis a boost.
Novartis announced today new subgroup analyses from its global Phase III PARAGON-HF study of patients with heart failure with preserved ejection fraction (HFpEF), also known as diastolic heart failure.6 The data suggest that, in specific subgroups, treatment with Entresto may result in greater reductions in heart failure hospitalizations and cardiovascular death, as compared to valsartan.
Novartis' Entresto, the clear-cut market leader in heart failure, has been soul-searching since its highly touted trial in an untreated population fell flat. Now, a surprise competitor has cropped up—but Merck and Bayer's upstart could actually give Novartis a boost.
Novartis' Entresto, the clear-cut market leader in heart failure, has been soul-searching since its highly touted trial in an untreated population fell flat. Now, a surprise competitor has cropped up—but Merck and Bayer's upstart could actually give Novartis a boost.
Novartis’ heart failure drug Entrestro (Sacubitril/valsartan) has narrowly missed its primary endpoint in a trial of patients with preserved ejection fraction (HFpEF).
Having hived off its animal health vaccine manufacturing and R&D to France’s Ceva, IDT Biologika is focused entirely on human products. To propel that effort, it has opened a new vaccine manufacturing facility in Germany.
Gene therapy Zolgensma is under the spotlight as Novartis launches what’s known as the world’s most expensive drug. And now, its top executive has offered an early glimpse into the rollout.
Valsartan products not currently recalled - Updated November 27, 2018
Debut ads helped drive the list-toppers for pharma TV spending in February. New commercials in ongoing campaigns for some big drugs, including Pfizer's breast cancer drug Ibrance and Novartis' heart-failure med Entresto—and the media spend put behind them—helped push those brands into the top 10.
Pharmaceutical co-crystals can improve the properties of active substances and ultimately make better medicines, says researcher.